{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-277030","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.404255+00:00","generated_at":"2026-06-22T09:08:42.792399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DBV Technologies Q3 net loss $17.3M; cash $213M; VITESSE Phase 3 delayed by clinical hold","bullets":["Q3 net loss of $17.3M ($0.18 per share); nine-month net loss $57.0M ($0.79 per share).","Cash and cash equivalents $212.7M as of Sept 30, 2022, up from $77.3M at Dec 31, 2021.","Operating expenses decreased 22% in Q3 and 26% in first nine months vs prior year.","Partial clinical hold on VITESSE Phase 3 study; first patient screen not expected by year-end 2022.","Cash used in operating activities fell 35% YoY; cost containment measures cited."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-277030","json":"https://secwatch.observer/filing/0001193125-22-277030.json","markdown":"https://secwatch.observer/filing/0001193125-22-277030.md","text":"https://secwatch.observer/filing/0001193125-22-277030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/0001193125-22-277030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/d411212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:08:42.792399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a32055f0f7009d3b6ad8f170ea2e5e5c335c2a1f","claim":"DBV Technologies S.A. reported the third quarter of 2022 results: net income $(17.3) million, EPS $(0.18).","evidence_excerpt":"DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/0001193125-22-277030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Net income","value":"$(17.3) million"},{"label":"EPS","value":"$(0.18)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}